Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Peginterferon alfa-2a

Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S (2007) Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46 640-648... [Pg.104]

Jacobson IM, Everson GT, Gordon SC, Kauffman R, McNair L, Muir A, McHutchison JG (2007) Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naive subjects with hepatitis C. AASLD 58th Annual Meet, Abstract 177 Johnson M (2006) Response to Atazanavir/ritonavir versus lopinavir/ritonavir equivalent or different efficacy profiles by HUl. AIDS 20 1987... [Pg.105]

Fried MW, Shiftman ML, Reddy KR, Smith C, Marinos G, Goncales EL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 975-982... [Pg.233]

Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda Ml (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343(23) 1666-1672... [Pg.346]

Chronic HCV- In combination with peginterferon alfa-2a for the treatment of adults with chronic HCV infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A). [Pg.1772]

Peginterferon alfa-2a and Ribavirin Tabiet Dosing Recommendations... [Pg.1772]

Ribavirin tablets/Peginterferon alfa-2a Ribavirin tablets/peginterferon alfa-2a combination therapy is contraindicated in patients with autoimmune hepatitis and... [Pg.1777]

Capsules/Tablets/Oral solution-There are significant adverse events caused by ribavirin capsules/interferon alfa-2b or peginterferon alfa-2b therapy, and ribavirin tablets/peginterferon alfa-2a therapy, including severe depression and suicidal ideation, hemolytic anemia, suppression of bone marrow function, autoimmune and infectious disorders, pulmonary dysfunction, pancreatitis, and diabetes. [Pg.1778]

Pancreatitis Suspend ribavirin, interferon alfa-2b, peginterferon alfa-2b, or peginterferon alfa-2a therapy in patients with signs and symptoms of pancreatitis and discontinue in patients with confirmed pancreatitis. [Pg.1779]

Capsules/Tablets/Oral solution-The safety and efficacy of ribavirin and interferon alfa-2b or peginterferon alfa-2a combination therapy for the treatment of HCV have not been established in patients coinfected with HIV or HBV. [Pg.1782]

Alpha interferons, including peginterferon alfa-2a, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. [Pg.1980]

Closely monitor patients with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping peginterferon alfa-2a (see Warnings and Adverse Reactions). [Pg.1981]

Chronic hepatitis C monoinfection The recommended dose of peginterferon alfa-2a is 180 meg (1 ml or 0.5 ml prefilled syringe) once weekly for 48 weeks by subcutaneous administration in the abdomen or thigh. [Pg.1981]

A patient should self-inject peginterferon alfa-2a only if the physician determines that it is appropriate, the patient agrees to medical follow-up as necessary, and training in proper injection technique has been provided. [Pg.1981]

Peginterferon alfa-2a/Ribavirin tablet combination The recommended dose of peginterferon alfa-2a when used in combination with ribavirin tablets is 180 meg (1 mL vial or 0.5 mL prefilled syringe) subcutaneously once weekly. The recommended dose of ribavirin and duration for the peginterferon alfa-2a/ribavirin tablet combination therapy is based on viral genotype. [Pg.1981]

Peginterferon alfa-2a Dose reduction to 135 meg peginterferon alfa-2a is recommended if the neutrophil count is less than 750 cells/mm. For patients with absolute neutrophil count (ANC) values below 500 cells/mm, suspend treatment until ANC values return to more than 1000 cells/mm. Initially reinstitute therapy at 90 meg peginterferon alfa-2a, and monitor the neutrophil count. [Pg.1982]

Dose reduction to 90 meg peginterferon alfa-2a is recommended if the platelet count is less than 50,000 cells/mm. Cessation of therapy is recommended when platelet count is below 25,000 cells/mm. ... [Pg.1982]

Guidelines for Modification or Discontinuation of Peginterferon alfa-2a and for Scheduling Visits for Patients with Depression... [Pg.1983]

Combination therapy with ribavirin tabiets-The recommended dose when used in combination with ribavirin tablets is peginterferon alfa-2a 180 meg subcutaneously once weekly and oral ribavirin tablets 800 mg daily given in 2 divided doses for a total of 48 weeks, regardless of genotype. Because ribavirin absorption increases when administered with a meal, patients are advised to take ribavirin with food. [Pg.1984]

Peginterferon Alfa-2a Hematological Dose Modification Guidelines... [Pg.1985]

Renal function impairment- In patients with end-stage renal disease requiring hemodialysis, dose reduction to 135 meg peginterferon alfa-2a is recommended. Closely monitor for signs and symptoms of interferon toxicity. Do not use ribavirin in patients with creatinine clearance less than 50 mL/min. [Pg.1987]

Liver function impairment - In patients with progressive ALT increases above baseline values, reduce the dose of peginterferon alfa-2a to 135 meg. Immediately discontinue therapy if ALT increases are progressive despite dose reduction or are accompanied by increased bilirubin or evidence of hepatic decompensation. [Pg.1987]

Metabolism/Excretion-The mean systemic clearance in healthy subjects given peginterferon alfa-2a was 94 mL/h. The mean terminal half-life after subcutaneous dosing in patients with chronic hepatitis C was 80 hours (range, 50 to 140 hours). [Pg.1988]

Elderly The AUC was increased from 1295 to 1663 ng h/mL in subjects older than 62 years of age taking 180 meg peginterferon alfa-2a, but peak concentrations were similar (9 vs 10 ng/mL) in those older and younger than 62 years of age. [Pg.1988]

Peginterferon alfa-2a Contraindicated for use in neonates and infants because it contains benzyl alcohol (see Warninasl. [Pg.1988]

See other pages where Peginterferon alfa-2a is mentioned: [Pg.233]    [Pg.236]    [Pg.237]    [Pg.237]    [Pg.240]    [Pg.240]    [Pg.329]    [Pg.341]    [Pg.342]    [Pg.343]    [Pg.344]    [Pg.345]    [Pg.1773]    [Pg.1980]    [Pg.1985]    [Pg.1985]    [Pg.1985]    [Pg.1988]    [Pg.1988]    [Pg.1989]   
See also in sourсe #XX -- [ Pg.59 , Pg.64 , Pg.65 ]



SEARCH



Peginterferon

Peginterferon alfa

© 2024 chempedia.info